← pool

🤖 In-vivo CRISPR proof point starts programmable biology

The first successful in-vivo infusion of a gene editor (Intellia's amyloidosis trial) converts CRISPR from theory to a working platform — an 'AWSification' of biology where the toolchain stacks and biological problems become programming problems. mRNA COVID vaccines are the first product of that stack, not the last.

0 CONVICTION
peaked 64.9 WATCH
EMBER
band
▲ LONG NTLA
expression · bullish tech
WRONG
result · return -54.4% · vs SPY -49.6%
2022-07-30
born 2021-07-30 (E42) → window closed

⚖ Why this result

fully deterministic — computed from daily closes on the scoring date; nothing below is editable or hand-set

  1. Window: 2021-07-30 → 2022-07-30 — first mention + 12-month horizon, then the window locks.
  2. The call: ▲ LONG NTLA (primary play). NTLA fell 54.4% over the window → return (sign flipped for a SHORT) = -54.4% (the call lost money).
  3. Benchmark: holding SPY over the same window returned -4.7% → vs SPY = -54.4 − (-4.7) = -49.6% — what this call made or lost against just owning the index. This is the number the result uses.
  4. Rule fired:
    · RIGHT — return ≥ +10% AND beat SPY by 5+
    · HALF — return ≥ +5% OR beat SPY at all
    ▶ WRONG — everything else
  5. Credit: supporters of a WRONG earn 0 each, opposers the opposite — this feeds the scoreboard. supported: Chamath, Friedberg, Sacks

Conviction timeline

bands: green ≥ 65 · watch ≥ 45 · ember ≥ 15

Plays vs SPY · % since first mention (2021-07-30)

Plays

expressionsymbolkindrelevancerationale
▲ LONG NTLAstock PRIMARY Chamath names Intellia by name as the company behind the breakthrough
▲ LONG BEAMstock adjacent base-editing next-gen play on the same toolchain thesis
▲ LONG CRSPstock adjacent largest CRISPR pure-play; platform read-through
▲ LONG EDITstock adjacent gene-editing peer levered to the same validation
▲ LONG MRNAstock adjacent Sacks's leg of the thesis: mRNA platform expands well beyond COVID vaccines

Mention log newest first

Friedberg
Friedberg tech 55% · n=66 · E71 (2022-03-05) · explicit_prediction · strength 2 ▶ 1:23:38 SUPPORT · horizon 120mo
“I think that over the long run, we can get the cost of cell therapies below 5,000 bucks. ... And this is kind of the beginning of what will likely be a multi-decade kind of new therapeutic modality that's, you know, accelerating.”
Friedberg
Friedberg tech 55% · n=66 · E68 (2022-02-19) · explicit_prediction · strength 3 ▶ 1:12:56 SUPPORT
“And there are a lot of therapies that are underway right now to actually use gene editing to induce that mutation in people's blood cells and in their bone marrow without needing to give them a whole transplant. ... there are hundreds of cell-based therapies coming to market over the next few years, they're all in late stage clinical trials as well as gene editing.”
Friedberg
Friedberg tech 55% · n=66 · E63 (2022-01-15) · sentiment · strength 1 ▶ 1:16:18 SUPPORT
“Now that we have gene editing and potentially have the ability to grow biological matter in bioreactors, it's going to be tremendous.”
Sacks
Sacks tech 39% · n=53 · E60 (2021-12-23) · sentiment · strength 1 ▶ 1:17:36 SUPPORT
“Well, you know, I originally had the CRISPR gene in anything, but Chamath already mentioned that.”
Chamath
Chamath tech 45% · n=84 · E60 (2021-12-23) · sentiment · strength 2 ▶ 40:43 SUPPORT
“My best science breakthrough is that this year, we actually were able to inject in vivo, so in the body genetic code for CRISPR. ... That's pretty incredible stuff that you can make something, put it into your body, and then your body does the work of editing out the bad genes.”
Friedberg
Friedberg tech 55% · n=66 · E59 (2021-12-17) · explicit_prediction · strength 3 ▶ 1:09:02 SUPPORT · horizon 120mo
“And now the floodgates are open. And this is incredible because the frontiers in RNA over the next decade could change the course of how we treat disease and change the course of outcomes for many diseases, from genetic diseases all the way through to cancers. ... we've now got, I think, a validation in the market and acceptance from consumers that this technology could transform the industry in the same way that Genentech transformed the pharma industry with biologic drugs in the 80s and 90s.”
Sacks
Sacks tech 39% · n=53 · E42 (2021-07-30) · explicit_prediction · strength 2 ▶ 45:21 SUPPORT
“I mean, I think what it shows is that these COVID vaccines are just the first product, the first breakthrough product of this mRNA technology. There's going to be a lot more.”
Chamath
Chamath tech 45% · n=84 · E42 (2021-07-30) · explicit_prediction · strength 3 ▶ 42:30 SUPPORT
“So I think what we're saying is that we're seeing this platformization, this AWSification of a biological toolchain with things like CRISPR and all of the other modalities that need to stack on top of it so that the next person can view it as a programming problem. ... But this was an enormously important breakthrough because it validated a lot of what CRISPR was beyond a lot of theoretical innovation that up until now was basically what it was known for.”

Who built this conviction

each voice's total push on the score, in conviction points across every mention — supports and opposes · share = % of all mention-driven movement

Chamath
Chamath 45%
2 scoring events · 47% of moves
+49.7 → net +49.7
Friedberg
Friedberg 55%
4 scoring events · 36% of moves
+38.8 → net +38.8
Sacks
Sacks 39%
2 scoring events · 17% of moves
+18.3 → net +18.3

⏳ decay drained -74.3 over the idea's life — that's time passing, attributed to no one

Score events

episodekindΔafternote
E42 2021-07-30 init +42.0 42.0 E42 born by Chamath (explicit_prediction x3)
E42 2021-07-30 reinforce +13.1 55.0 E42 Sacks support x2 (new voice)
E43 2021-08-06 decay -2.2 52.8 E43 silent
E44 2021-08-28 decay -2.1 50.7 E44 silent
E45 2021-09-04 decay -2.0 48.7 E45 silent
E46 2021-09-14 decay -1.9 46.8 E46 silent
E47 2021-09-18 decay -1.9 44.9 E47 silent
E49 2021-10-02 decay -1.8 43.1 E49 silent
E50 2021-10-09 decay -1.7 41.4 E50 silent
E51 2021-10-16 decay -1.7 39.7 E51 silent
E52 2021-10-23 decay -1.6 38.1 E52 silent
E53 2021-10-30 decay -1.5 36.6 E53 silent
E54 2021-11-06 decay -1.5 35.1 E54 silent
E55 2021-11-13 decay -1.4 33.7 E55 silent
E56 2021-11-20 decay -1.3 32.4 E56 silent
E57 2021-12-04 decay -1.3 31.1 E57 silent
E58 2021-12-11 decay -1.2 29.8 E58 silent
E59 2021-12-17 reinforce +18.9 48.8 E59 Friedberg support x3 (new voice)
E60 2021-12-23 reinforce +7.7 56.5 E60 Chamath support x2
E60 2021-12-23 reinforce +5.2 61.7 E60 Sacks support x1
E61 2021-12-29 decay -2.5 59.2 E61 silent
E62 2022-01-08 decay -2.4 56.9 E62 silent
E63 2022-01-15 reinforce +5.2 62.0 E63 Friedberg support x1
E64 2022-01-22 decay -2.5 59.6 E64 silent
E65 2022-01-29 decay -2.4 57.2 E65 silent
E66 2022-02-05 decay -2.3 54.9 E66 silent
E67 2022-02-12 decay -2.2 52.7 E67 silent
E68 2022-02-19 reinforce +8.5 61.2 E68 Friedberg support x3
E70 2022-02-24 decay -2.4 58.8 E70 silent
E71 2022-03-05 reinforce +6.2 64.9 E71 Friedberg support x2
E72 2022-03-19 decay -2.6 62.3 E72 silent
E73 2022-03-26 decay -2.5 59.9 E73 silent
E74 2022-04-01 decay -2.4 57.5 E74 silent
E75 2022-04-09 decay -2.3 55.2 E75 silent
E76 2022-04-16 decay -2.2 53.0 E76 silent
E77 2022-04-23 decay -2.1 50.8 E77 silent
E78 2022-04-30 decay -2.0 48.8 E78 silent
E79 2022-05-07 decay -2.0 46.8 E79 silent
E80 2022-05-13 decay -1.9 45.0 E80 silent
E81 2022-05-23 decay -1.8 43.2 E81 silent
E82 2022-05-24 decay -1.7 41.4 E82 silent
E84 2022-06-24 decay -1.7 39.8 E84 silent
E85 2022-06-30 decay -1.6 38.2 E85 silent
E86 2022-07-08 decay -1.5 36.7 E86 silent
E87 2022-07-14 decay -1.5 35.2 E87 silent
E88 2022-07-22 decay -1.4 33.8 E88 silent
E89 2022-07-29 decay -1.4 32.4 E89 silent